BHVN Quote, Financials, Valuation and Earnings

Structure Therapeutics has a net margin of -- compared to Biohaven's net margin of --. Biohaven's return on equity of -- beat Structure Therapeutics's return on equity of --.

Biohaven has a consensus price target of $63.47, signalling upside risk potential of 117.72%. On the other hand Structure Therapeutics has an analysts' consensus of $80.15 which suggests that it could grow by 280.78%. Given that Structure Therapeutics has higher upside potential than Biohaven, analysts believe Structure Therapeutics is more attractive than Biohaven.

Biohaven has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Structure Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Biohaven has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Structure Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biohaven pays -- of its earnings as a dividend. Structure Therapeutics pays out -- of its earnings as a dividend.

Biohaven quarterly revenues are --, which are smaller than Structure Therapeutics quarterly revenues of --. Biohaven's net income of -$186.8M is lower than Structure Therapeutics's net income of -$36.5M. Notably, Biohaven's price-to-earnings ratio is -- while Structure Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biohaven is -- versus -- for Structure Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -- compared to Biohaven's net margin of 32.59%. Biohaven's return on equity of -- beat Eli Lilly and's return on equity of 80.24%.

Biohaven has a consensus price target of $63.47, signalling upside risk potential of 117.72%. On the other hand Eli Lilly and has an analysts' consensus of $1,006.63 which suggests that it could grow by 23.74%. Given that Biohaven has higher upside potential than Eli Lilly and, analysts believe Biohaven is more attractive than Eli Lilly and.

Biohaven has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.817%.

Biohaven has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.50 per share. Biohaven pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Biohaven quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Biohaven's net income of -$186.8M is lower than Eli Lilly and's net income of $4.4B. Notably, Biohaven's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 69.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biohaven is -- versus 16.33x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -- compared to Biohaven's net margin of 2.31%. Biohaven's return on equity of -- beat Pfizer's return on equity of 8.91%.

Biohaven has a consensus price target of $63.47, signalling upside risk potential of 117.72%. On the other hand Pfizer has an analysts' consensus of $31.32 which suggests that it could grow by 21.76%. Given that Biohaven has higher upside potential than Pfizer, analysts believe Biohaven is more attractive than Pfizer.

Biohaven has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer has a beta of 0.613, suggesting its less volatile than the S&P 500 by 38.72%.

Biohaven has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.57% to investors and pays a quarterly dividend of $0.43 per share. Biohaven pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Biohaven quarterly revenues are --, which are smaller than Pfizer quarterly revenues of $17.8B. Biohaven's net income of -$186.8M is lower than Pfizer's net income of $410M. Notably, Biohaven's price-to-earnings ratio is -- while Pfizer's PE ratio is 18.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biohaven is -- versus 2.30x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of -- compared to Biohaven's net margin of --. Biohaven's return on equity of -- beat Viking Therapeutics's return on equity of --.

Biohaven has a consensus price target of $63.47, signalling upside risk potential of 117.72%. On the other hand Viking Therapeutics has an analysts' consensus of $99.29 which suggests that it could grow by 221.44%. Given that Viking Therapeutics has higher upside potential than Biohaven, analysts believe Viking Therapeutics is more attractive than Biohaven.

Biohaven has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.651%.

Biohaven has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biohaven pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Biohaven quarterly revenues are --, which are smaller than Viking Therapeutics quarterly revenues of --. Biohaven's net income of -$186.8M is lower than Viking Therapeutics's net income of -$35.4M. Notably, Biohaven's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biohaven is -- versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.